Riskpilot← Back to searchSign inGet full accessARA Life Science AB
ABIn liquidationOrg 5566440730Kungsgatan 62Translation and interpretation activities · NACE 7430Est. 20032 employees
Revenue 2025
SEK 0
EBITDA margin
—
-120% vs 2024
Equity ratio
67.2%
Financial strength
Net profit 2025
SEK -20K
-125% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -20K | -120% |
| Net profit | SEK -20K | -125% |
| Total assets | SEK 122K | -44% |
| Equity | SEK 82K | -55% |
| Employees | 2 | — |
Legal name
ARA Life Science AB
Org number
5566440730
Legal form
Aktiebolag
NACE code
7430 · Translation and interpretation activities
Founded
6 maj 2003
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall bedriva konsult- och bemanningsverksamhet med specialistkompetens inom området life science ävensom idka därmed förenlig verksamhet.
Address
Kungsgatan 62
Phone
+4618186618
Email
lars@anstrands.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 152 | 166 | 171 | 88 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 136 | 140 | 150 | 99 | −20 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 136 | 140 | 150 | 99 | −20 |
| Net financials | −1 | — | — | — | — |
| Profit before tax | 135 | 140 | 150 | 99 | −20 |
| Tax | −29 | −29 | −31 | −20 | −0 |
| Net profit | 106 | 111 | 119 | 79 | −20 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 297 | 294 | 295 | 216 | 122 |
| Equity | 213 | 214 | 223 | 182 | 82 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 84 | 81 | 72 | 35 | 41 |
| Total debt | 84 | 81 | 72 | 35 | 41 |
EBITDA margin
-2000000.0%
This company
15.8%
Market median
-12658328% vs market
20212025
Equity ratio
67.2%
This company
38.2%
Market median
+76% vs market
20212025
Return on equity
-24.4%
This company
18.4%
Market median
-233% vs market
20212025
Net profit margin
-2000000.0%
This company
8.1%
Market median
-24691458% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LG Liquidator | Liquidator | 2026 |
| Former (1) | ||
PG Audit | Audit | 2022 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2022 – 2026 | |
| Board of Directors | 2022 – 2026 | |
| Chairman | 2022 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ARA Life Science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Gustaf Hammar | Audit | 0 companies |
| Lars Gösta Ånstrand | Liquidator | 0 companies |
| Gail Isabel Reid Adam | Board of Directors | 0 companies |
| Carl Gunnar Walter C Risinger | Board of Directors | 0 companies |
| Maria Kristina Andersson Ödman | Chairman | 0 companies |